Announcing the upcoming opening of the MMRC MyDRUG clinical trial, which will enroll patients with recurrent Multiple Myeloma

VCS Practice Blog

December 12, 2018
Virginia Cancer Specialists » VCS Practice News » Clinical Trials and Research » VCS Practice News » Clinical Trials Search » Announcing the upcoming opening of the MMRC MyDRUG clinical trial, which will enroll patients with recurrent Multiple Myeloma

Virginia Cancer Specialists (VCS) is the only community oncology program in the country that is part of the Multiple Myeloma Research Consortium (MMRC), a collaboration of leading academic medical centers offering state of the art treatment and partnering in the latest clinical trials for patients with multiple myeloma (MM).

As part of this effort we are pleased to announce the upcoming opening of the MMRC MyDRUG clinical trial, which will enroll patients with recurrent MM. This ambitious multi-center protocol will utilize genetic profiling to identify specific molecular markers to tailor a patients treatment by incorporating next generation targeted therapy. We are pleased to offer our patients this cutting edge clinical trial at the forefront of precision medicine.

If you are interested in learning more about the trial please contact us here to set up a consultation. Currently applications for this clinical trial are waiting in an official Clinical Trial start date (To Be Announced).

Read the full press release here:  The Multiple Myeloma Research Foundation (MMRF) Launches MyDRUG — First-ever Platform Clinical Trial in Multiple Myeloma – Trial represents the pinnacle of the MMRF’s end-to-end precision medicine model, which identified and validated the targets being studied in MyDRUG